)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Ginkgo Bioworks
Ginkgo Bioworks (DNA) investor relations material
Ginkgo Bioworks Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary26 Feb, 2026
Executive summary
Strategic focus shifted to autonomous labs as the core platform, with divestiture of the biosecurity business to enable targeted investment and operational focus on robotics and AI-driven lab automation.
Major contract wins include a $47 million deal with Pacific Northwest National Laboratory and a high-profile collaboration with OpenAI deploying GPT-5, demonstrating leadership in AI-integrated lab automation and achieving a 40% reduction in protein production costs.
Significant restructuring and cost controls over the past two years reduced annual cash burn by 55%, positioning the company for sustainable investment in core growth areas.
Expansion of the Boston autonomous lab from 50 to 100 racks is underway, aiming to showcase scalability and attract further commercial and research partnerships.
Partnerships announced with ARPA-H, University of Illinois Urbana-Champaign, Carnegie Mellon, Agricen, and Deep Origin, and launch of Datapoints business serving top pharma customers.
Financial highlights
Full year 2025 revenue was $170 million, down 25% year-over-year; Q4 2025 revenue was $33 million, down 24% from Q4 2024.
Cell engineering revenue for FY2025 was $133 million, down 24% year-over-year; Biosecurity revenue was $37 million, down 30%.
Adjusted EBITDA improved to -$36 million in Q4 2025 from -$57 million in Q4 2024; full-year Adjusted EBITDA was -$167 million, up from -$293 million in 2024.
Full year 2025 GAAP net loss was $(313) million, improved from $(547) million in 2024.
Cash burn for 2025 was $171 million, a 55% reduction from $383 million in 2024; year-end cash and equivalents totaled $423 million.
Outlook and guidance
No revenue guidance for 2026; focus is on cash burn, expected to be $125 million–$150 million, reflecting continued cost discipline and investment in autonomous labs.
2026 priorities include completing the biosecurity business divestiture, expanding autonomous lab capacity, and commercializing lab automation offerings through direct sales and cloud lab services.
Biosecurity divestiture's impact on 2026 cash burn
Quantify 2026 autonomous lab capacity increase
Breakdown of 2025 Cell Engineering revenue decline
How to accelerate autonomous lab adoption by pharma?
Why guide on cash burn instead of revenue for 2026?
What is the long-term vision for the Biosecurity stake?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next Ginkgo Bioworks earnings date
Q1 20265 May, 2026
Ginkgo Bioworks
Next Ginkgo Bioworks earnings date
Q1 20265 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Ginkgo Bioworks Holdings, Inc, a biomolecular engineering company, develops biological manufacturing technologies to program cells for molecular manufacturing systems. Ginkgo Bioworks Holdings software engineering platform uses the widely used programming language Python and its library of bioinformatics functions and statistical methods. Ginkgo Bioworks' programs are designed to modify bacterial genes to make organic compounds such as vanillin, scents to produce civetone in bacteria, Beta-carotene and lycopene in yeast cells, gluconic acid in E. coli; and shikimic acid and artemisinic acid in yeast cells. The company sells its products to pharmaceutical companies including AstraZeneca Group and Eli Lilly & Co; chemical companies including Firmenich SA; flavor, aroma, and fragrance companies; craft breweries; and others.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage